IOVA — IOVANCE BIOTHERAPEUTICS, INC.
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 1425205 ·
Last close
$4.07
Market Cap
$1.82B
52W High
$5.64
52W Low
$3.28
ADV30
16,218,487
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 71,430,000 | 28,932,000 | -81,043,000 | -79,045,000 | 925,665,000 | 196,508,000 | 203,911,000 |
| Dec 2025 | 86,771,000 | 43,660,000 | -73,460,000 | -71,904,000 | 913,170,000 | 163,078,000 | 214,587,000 |
| Sep 2025 | 67,455,000 | 28,978,000 | -89,758,000 | -91,253,000 | 904,948,000 | 158,134,000 | 202,661,000 |
| Jun 2025 | 59,952,000 | 3,288,000 | -113,774,000 | -111,658,000 | 907,437,000 | 132,469,000 | 208,949,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-302,408,000
Investing CF
$47,496,000
Financing CF
$300,773,000
CapEx
$-33,836,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.12
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-2,775,530,000
Inventory
$51,678,000
Receivables
$82,448,000
ST Investments
$133,902,000
EBIT TTM
$-398,213,000
Pretax Income TTM
$-393,049,000
Interest Exp TTM
—
Analysts
10
Yahoo Snapshot (yfinance, live)
Total Revenue
$285,608,000
EBITDA
$-321,622,016
Free Cash Flow
$-149,067,872
Enterprise Value
$1,551,599,744
Total Cash
$313,443,008
Total Debt
$47,776,000
Shares Out
446,502,396
Trailing EPS
$-0.92
Book Value
$1.65
ROE
-47.5%
ROA
-23.6%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 263,502,000 | -398,213,000 | -390,978,000 | 913,170,000 | 214,587,000 | — | -302,408,000 |
| Dec 2024 | 164,070,000 | -395,278,000 | -372,177,000 | 910,426,000 | 200,021,000 | — | -352,977,000 |
| Dec 2023 | 1,189,000 | -460,559,000 | -444,037,000 | 780,351,000 | 195,738,000 | — | -361,820,000 |
| Dec 2022 | 0 | -398,878,000 | -395,893,000 | 663,982,000 | 164,344,000 | — | -292,757,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-0.32
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| MESO | MESOBLAST LTD | $1.84B | $14.17 | — |
| IMCR | Immunocore Holdings plc | $1.72B | $33.81 | — |
| ADMA | ADMA BIOLOGICS, INC. | $1.96B | $8.46 | — |
| TSHA | Taysha Gene Therapies, Inc. | $1.68B | $5.86 | — |
| RXRX | RECURSION PHARMACEUTICALS, INC. | $1.57B | $3.00 | — |
News headlines (Yahoo Finance, 1h cache)
Iovance Biotherapeutics (IOVA) Stock May Be Cheap As Sales Ramp Remains Key
2026-08-02 05:08 · Yahoo
Do Mixed Q2 Expectations Alter Iovance Biotherapeutics' (IOVA) TIL Leadership Narrative?
2026-08-01 16:11 · Yahoo
Iovance Biotherapeutics (IOVA) Heads Into Earnings With Its T Cell Therapy Story And Valuation In Focus
2026-08-01 15:12 · Yahoo
Neurocrine Biosciences Q2 Earnings Call Highlights
2026-08-01 01:02 · Yahoo
Will Iovance Biotherapeutics (IOVA) Report Negative Q2 Earnings? What You Should Know
2026-07-30 14:00 · Yahoo
Iovance Biotherapeutics to Report Second Quarter 2026 Financial Results and Corporate Updates on Thursday, August 6, 2026
2026-07-30 12:00 · Yahoo
Is Apogee Therapeutics Inc. (APGE) Stock Outpacing Its Medical Peers This Year?
2026-07-28 13:40 · Yahoo
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
2026-07-17 21:15 · Yahoo
Iovance Biotherapeutics (IOVA) Updates its Corporate Presentation, Here’s What’s Important to Note
2026-07-09 17:51 · Yahoo
This Stock Is Up 74% This Year: Is It Too Late to Buy?
2026-07-08 23:05 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.